论文部分内容阅读
目的：观察心房颤动（房颤）包括阵发性房颤和持续性房颤导管消融患者远期血栓栓塞的情况，以了解房颤导管消融患者远期血栓栓塞与CHA2DS2-VASC评分的关系，从而指导房颤导管消融患者远期抗凝策略的选择。 方法：入选2000-01至2009-05于我院行房颤导管射频消融治疗患者321例，其中阵发性房颤261例，持续性房颤60例，平均随访（66.7±26.9）个月，根据房颤是否复发分为无复发组204例和复发组117例，观察其血栓栓塞情况及与脑血管意外危险因素CHA2DS2-VASC评分的关系。 结果：无复发组栓塞发生率明显低于复发组栓塞发生率（1.96%vs 7.69%，P=0.017），差异有统计学意义。无复发组与复发组中CHA2DS2-VASC＜2分者栓塞发生率均明显低于CHA2DS2-VASC≥2分者（0%vs 5%，P=0.023；4.45%vs 17.24%，P=0.041），差异均有统计学意义。无复发组中CHA2DS2-VASC＜2分者栓塞发生率明显低于复发组中CHA2DS2-VASC＜2分者栓塞发生率（0%vs 4.45%，P=0.029），差异有统计学意义。无复发组中CHA2DS2-VASC≥2分者栓塞发生率与复发组中CHA2DS2-VASC≥2分者栓塞发生率（5%vs 17.24%，P=0.054），差异无统计学意义。 结论：在接受导管消融的房颤患者中，长期随访没有房颤复发的患者血栓栓塞发生率明显降低。CHA2DS2-VASC评分在评价房颤射频消融术后患者远期血栓栓塞发生率方面有重要意义。提示房颤射频消融术后远期维持窦性心律患者中CHA2DS2-VASC＜2分者可以酌情考虑停用华法林，但对于CHA2DS2-VASC≥2分者，仍继续应用华法林抗凝获益更大。“,”The Long-term Thromboembolic Event Analysis in Atrial Fibrillation Patients With Radiofrequency Catheter Ablation Objective: To observe the thromboembolic event in atrial fibrillation (AF) patients with long-term successful radiofrequency catheter ablation (RFCA), and to study the relationship between thromboembolic event and CHA2DS2-VASC score in order to guide the anticoagulation strategy for AF patients. Methods: A total of 321 AF patients who received RFCA in our hospital from 2000-01 to 2009-05 were studied. There were 261 patients with paroxysmal AF and 60 with persistent AF, they were followed-up for (66.7±26.9) months. The patients were divided into 2 groups according to AF recurrence condition as Non-recurrence group, n=204 and Recurrence group, n=117. The relationship between thromboembolic event and CHA2DS2-VASC score was studied. Results: The Non-recurrence group had significantly lower rate of thromboembolism than that in Recurrence group (1.96% vs 7.69%), P=0.017. In both groups, the patients with CHA2DS2-VASC score < 2 had much lower rate of thromboembolism than those with CHA2DS2-VASC score ≥ 2, (0% vs 5%), P=0.023 and (4.45% vs 17.24%), P=0.041. The patients with CHA2DS2-VASC score<2 in Non-recurrence group had lower rate of thromboembolism than those in Recurrence group (0%vs 4.45%), P=0.029. The rate of thromboembolism had no statistic meaning between 2 groups in patients with CHA2DS2-VASC score≥2 (5%vs 17.24%), P=0.054. Conclusion: The AF patients who received RFCA without AF recurrence in long-term follow-up had the lower rate of thromboembolic event, CHA2DS2-VASC score was important for evaluating such event. The patients with CHA2DS2-VASC score < 2 could consider stopping warfarin anticoagulation, while the patients with CHA2DS2-VASC score ≥ 2 might be beneifted for warfarin anticoagulation.